UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000019071
Receipt No. R000022051
Official scientific title of the study The effect of ipragliflozin on ectopic fat accumulation in non-obese type 2 diabetic patients with increased visceral fat
Date of disclosure of the study information 2015/10/15
Last modified on 2017/02/04 (Ver. 5)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study The effect of ipragliflozin on ectopic fat accumulation in non-obese type 2 diabetic patients with increased visceral fat
Title of the study (Brief title) SGLT2 inhibitor and ectopic fat accumulation in diabetes
Region
Japan

Condition
Condition Type 2 diabetes
Classification by specialty
Endocrinology and Metabolism
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To investigate whether ipragliflozin could reduce ectopic fat accumulation in non-obese type 2 diabetic patients
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes The change of epicaridial fat volume from baseline at 12 weeks
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Ipragliflozin 50 mg for 12 weeks
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
75 years-old >
Gender Male and Female
Key inclusion criteria Type 2 diabetes with BMI < 25.0 kg/m2 and HbA1c 6.5-9.0% and visceral fat area equal to or greater than 100 cm2
Key exclusion criteria Patients who are taking SGLT2 inhibitors
Patients with insulin treatment
Patients with severe diabetic retinopathy
Patients who are hypersensitive to SGLT2 inhibitors
Patients with cogestive heart failure (NYHA classification class III or IV)
Patients with active infection, malignancy, severe liver or renal diseases
Patients who had recently received operation or had severe trauma
Patients who had experienced atherothrombotic events including myocardila infarction and/or stroke
Patients with severe ketosis or diabetic coma/pre-coma
Patients who are unable to figure out the consent due to dementia or impairment of consciousness
Pregnant women, lactating woman, women who are planning to get pregnant
Patients who were judged inadequate to enroll in the study by medical doctors
Target sample size 20

Research contact person
Name of lead principal investigator Ryotaro Bouchi
Organization Tokyo Medical and Dental University
Division name Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences
Address 1-5-45 Yushima, Bunkyoku, Tokyo, Japan
TEL 03-3813-6111
Email bouchi.mem@tmd.ac.jp

Public contact
Name of contact person Ryotaro Bouchi
Organization Tokyo Medical and Dental University
Division name Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences
Address 1-5-45 Yushima, Bunkyoku, Tokyo, Japan
TEL 03-3813-6111
Homepage URL
Email bouchi.mem@tmd.ac.jp

Sponsor
Institute Tokyo Medical and Dental University
Institute
Department

Funding Source
Organization Astellas Pharma Inc.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2015 Year 10 Month 15 Day

Progress
Recruitment status Completed
Date of protocol fixation
2015 Year 08 Month 25 Day
Anticipated trial start date
2015 Year 10 Month 15 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information

Management information
Registered date
2015 Year 09 Month 19 Day
Last modified on
2017 Year 02 Month 04 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022051